LAMEA Nifedipine Market Size, Share & Trends Analysis Report By Type (Nifedipine Controlled-Release Tablets, Nifedipine Extended Action Tablets), By Application (Primary Pulmonary Hypertension, Heart Failure, Raynaud’s Syndrome, Cephalalgia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region (North America, Asia-Pacific, Europe, Latin America, The Middle East and Africa) and By Country (Brazil, Mexico, Argentina, Chile, Colombia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Rest of LAMEA) Forecasts, 2026-2034

Market Dynamics

Market Drivers

• Increased Hypertension in the Region: The Middle East has a high prevalence of hypertension. The high prevalence of hypertension in the Middle East is thought to be due to a combination of variables, including longevity, infection control, sedentary lifestyle, dietary changes, and social stress. As a result, the need for medication is predicted to rise, as is the demand for Nifedipine in the region.

• As the demand for calcium channel blocker drugs develops, product demand is likely to rise as well: Nifedipine is an effective treatment for a variety of illnesses, including high blood pressure (hypertension), heart attack, chilblain, cephalalgia, chest discomfort (angina), preterm labour, prinzmetal's angina (squeezing of blood vessels), and Raynaud's phenomenon (numbness of multiple body regions). Because of its usefulness, notably in the treatment of premature labour, the drug's total usage is increasing. It helps to prevent health problems that preemies are prone to as a result of their premature delivery by suppressing preterm labour by stopping muscle cell contractions. Calcium channel blockers and nifedipine may be in higher demand in Latin America and Middle East as a result of these causes.

Market Restraints

• Presence of Substitutes: Nifedipine, a dihydropyridine calcium channel blocker, was once one of the most widely used hypertension medications, but safety and tolerability concerns, as well as the introduction of new classes of antihypertensive medications and a growing body of data showing the mortality benefit of other classes, caused a drop in demand, and thus this is a significant restraint in the market's growth in the region.

Market Opportunities

• Favourable government assistance: Favourable government support would aid market expansion. For example, certain nations in the region have announced intentions to screen and treat more than 80% of hypertension patients by the end of 2025, and such programmes can present attractive prospects for the LAMEA market's leading players.

Segmental Analysis

The two varieties of nifedipine pills are nifedipine controlled-release tablets and nifedipine extended-action tablets. In 2021, the controlled-release pills of nifedipine had the most market share. Rising rates of hypertension and heart failure, the use of cutting-edge technology in pharmaceutical research, more funding from the government and international organisations, and increased public awareness about the importance of preventative treatment are all contributing to this significant increase.

Depending on the application, the section is divided into primary pulmonary hypertension, heart failure, Raynaud's disease, cephalalgia, and others. Primary pulmonary hypertension was the most common cause of pulmonary hypertension in 2021. Obesity, poor dietary habits, excessive junk food consumption, a lack of exercise, a surge in smoking and alcohol consumption among the younger population, and stress are all contributing factors. Increased government and corporate sector initiatives, as well as real programmes for the discovery of novel medications to treat hypertension and diabetes, are likely to move this field forward.

Hospital pharmacies, retail pharmacies, and other distribution channels make up the LAMEA nifedipine market. In 2020, hospital pharmacies dominated the regional market, which is predicted to grow at a quicker CAGR throughout the forecast period.

Request Customizationto receive a tailored report.

Speak to an Analystto discuss market opportunities.

Regional Analysis

By 2030, the LAMEA Nifedipine market is estimated to be worth USD 105.71 million, with a compound annual growth rate (CAGR) of 6.85% over the forecast period (2022–2030). In addition, the market for nifedipine in the Middle East and Africa is estimated to reach USD 90.37 million by 2030, rising at a CAGR of 6.64% over the forecast period (2022–2030). The market in the LAMEA area is being driven by an increase in the senior population, healthcare spending, the incidence of chronic conditions such as heart failure, arrhythmias, and hypertension, and healthcare awareness. Fattiness and diabetes are becoming increasingly common in the Middle East, especially in the Gulf region, which encompasses Kuwait, Saudi Arabia, Bahrain, Qatar, and the United Arab Emirates.

Raynaud's Syndrome causes a reduction in effective blood flow to the extremities, particularly the fingers and toes; this causes chilly, pale fingers and toes, which are followed by pain and redness when blood flow resumes. The underlying issue is constriction of the blood arteries in these places as a result of cold, stress, or some other factor. Raynaud's syndrome has become more common in South Africa in recent years, necessitating the use of calcium channel blockers for therapy, which has increased demand for Nifedipine in the country.

The Middle East and North African area have the highest diabetes prevalence in 2019, at 12.2%, and is forecast to see a 96% increase in diabetes prevalence between 2019 and 2045, second only to the African region, which is expected to see a 143% increase. Diabetes and hypertension have developed dramatically in nations such as Iran, Jordan, Saudi Arabia, and the United Arab Emirates, resulting in increased demand for Nifedipine.

Impact of Covid-19

The automotive industry is critical to the economy's growth. However, during the second and third quarters of 2020, the COVID-19 outbreak impacted the whole automotive supply chain, affecting new car sales in FY 2020.

South America is most affected by COVID-19, with Brazil leading the way, followed by Ecuador, Chile, Peru, and Argentina. South America's government (SAM) has taken a number of steps to protect its citizens and stem the spread of COVID-19. South America is expected to have fewer export revenues as commodity prices fall and export volumes fall, particularly to China, Europe, and the United States, which are all significant trading partners. The manufacturing industry, especially automotive manufacturing, has been damaged by containment measures in various South American countries. Due to the pandemic, major automotive manufacturers have also temporarily halted manufacturing in the region as a cost-cutting move. Furthermore, the automobile disc brake industry has been significantly affected in 2020 due to a lack of raw materials and supply chain disruption.

The Automotive Brake System control module of a vehicle is meant to alert the driver with a warning light if the system fails. The module itself is rarely defective; instead, the sensors or the wiring to the sensors are frequently defective. The most typical cause of dysfunction is when the Automotive Brake System is contaminated with particles or metal shavings. There is no signal continuity when sensor wiring is destroyed. Brake fluid becomes contaminated in corrosive situations, and the hydraulic unit fails to function.

List of Key and Emerging Players in LAMEA Nifedipine Market

• Boehringer Ingelheim GmbH
• AstraZeneca plc
• Pfizer Inc.
• GlaxoSmithKline plc